Amylyx Pharmaceuticals’ low blood sugar drug avexitide has delivered strong results in a late-stage trial. The experimental treatment cut hypoglycemic episodes by 55 percent versus placebo. The results came from a 78-patient trial involving people...
FDA approvals are driving a new phase in Indian pharma. They are helping companies expand beyond domestic markets and strengthen their presence in regulated markets
Hearzap today announced the successful completion of its acquisition of Amplifon India's hearing healthcare business. The acquisition took place after definitive agreement announced in May 2026, marking one of the most significant developments...
Tenet Diagnostics has received a major USD 30 million investment from Tata Capital Healthcare Fund III and Swiss impact investor Blue Earth Capital AG. The deal marks a fresh push into India’s growing diagnostics market. The investment will help...
CDMO platform expansion is gaining momentum at Piramal Pharma as the company takes majority control of Yapan Bio, the transaction turns Yapan Bio into a subsidiary and strengthens Piramal Pharma’s capabilities in vaccine and biologics development
India’s healthcare workforce is gaining a new pathway to international careers. OET and the International Institute of Medical Sciences and Technical Council (IIMSTC) have joined forces to support this goal
Plaque psoriasis patients in India may soon have a new treatment option. Optimus Pharma has received approval from the Drug Controller General of India (DCGI). The approval covers Tapinarof Cream 1% w/w for adult patients with plaque psoriasis.
The GLP-1 boom is pushing companies across consumer industries to rethink what people eat, drink, and buy. Weight-loss drugs are creating new demand beyond the pharmaceutical sector. Companies now see opportunities in nutrition, food, beverages...
AI innovation is accelerating across India’s drug development, approvals, medical devices and specialized healthcare ecosystem
Lung cancer trial development at AstraZeneca has hit a setback. The company discontinued its Phase III eVOLVE-Lung02 study of volrustomig with chemotherapy in metastatic non-small cell lung cancer
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")